Cybin completes acquisition of phase 1 dmt study from entheon biomedical

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biopharmaceutical company focused on progressing “psychedelics to therapeutics™”, today announced that, through its wholly-owned subsidiary cybin irl limited, it has completed the acquisition of a phase 1 n,n-dimethyltryptamine (“dmt”) study (the “acquisition”) from entheon biomedical corp. (cse: enbi) (otcqb: entbf) (fse: 1xu1) (“entheon”). this dmt study, which is the largest to date, is expecte
CYBN Ratings Summary
CYBN Quant Ranking